CN116745295A - Brm靶向化合物及相关使用方法 - Google Patents

Brm靶向化合物及相关使用方法 Download PDF

Info

Publication number
CN116745295A
CN116745295A CN202180087475.7A CN202180087475A CN116745295A CN 116745295 A CN116745295 A CN 116745295A CN 202180087475 A CN202180087475 A CN 202180087475A CN 116745295 A CN116745295 A CN 116745295A
Authority
CN
China
Prior art keywords
pyrazino
methyl
hydroxyphenyl
piperidin
dione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180087475.7A
Other languages
English (en)
Chinese (zh)
Inventor
陆亮
安德鲁·保罗·库姆斯
科里·霍华德·巴斯奇
鲁帕·谢蒂
戴超峰
克莱尔·拉佐·贝尔施
约翰·A·罗斯
丹妮尔·朱莉·贝姆·罗斯
梅松
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pruder Therapeutics Ltd
Original Assignee
Pruder Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pruder Therapeutics Ltd filed Critical Pruder Therapeutics Ltd
Publication of CN116745295A publication Critical patent/CN116745295A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN202180087475.7A 2020-11-06 2021-11-08 Brm靶向化合物及相关使用方法 Pending CN116745295A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063110688P 2020-11-06 2020-11-06
US63/110,688 2020-11-06
PCT/US2021/058424 WO2022099117A1 (en) 2020-11-06 2021-11-08 Brm targeting compounds and associated methods of use

Publications (1)

Publication Number Publication Date
CN116745295A true CN116745295A (zh) 2023-09-12

Family

ID=81456756

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180087475.7A Pending CN116745295A (zh) 2020-11-06 2021-11-08 Brm靶向化合物及相关使用方法

Country Status (10)

Country Link
US (1) US12448389B2 (cg-RX-API-DMAC10.html)
EP (1) EP4240743A1 (cg-RX-API-DMAC10.html)
JP (1) JP2023549341A (cg-RX-API-DMAC10.html)
KR (1) KR20230117577A (cg-RX-API-DMAC10.html)
CN (1) CN116745295A (cg-RX-API-DMAC10.html)
AU (1) AU2021376415A1 (cg-RX-API-DMAC10.html)
CA (1) CA3200685A1 (cg-RX-API-DMAC10.html)
IL (1) IL302669A (cg-RX-API-DMAC10.html)
MX (1) MX2023005301A (cg-RX-API-DMAC10.html)
WO (1) WO2022099117A1 (cg-RX-API-DMAC10.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116744929A (zh) * 2020-11-20 2023-09-12 福霍恩治疗公司 化合物及其用途
WO2026098598A1 (zh) * 2024-11-08 2026-05-15 正大天晴药业集团股份有限公司 含有三并杂环的化合物

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT4161935T (pt) * 2020-06-09 2025-08-14 Prelude Therapeutics Inc Compostos direcionados a brm e métodos de utilização associados
CA3211347A1 (en) 2021-03-19 2022-09-22 Erika Araujo Indazole based compounds and associated methods of use
JP2024539269A (ja) * 2021-10-22 2024-10-28 グルータクス セラピューティクス (シャンハイ) カンパニー、リミテッド Crbn e3リガーゼリガンド化合物、当該リガンド化合物に基づいて開発したタンパク質分解剤及びそれらの応用
PL4245756T3 (pl) * 2022-03-17 2025-02-17 Gilead Sciences, Inc. Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania
JP2025521091A (ja) * 2022-05-10 2025-07-08 プレリュード・セラピューティクス・インコーポレイテッド がんの治療のためのsmarca4タンパク質分解因子としての6,6a,7,8,9,10-ヘキサヒドロ-5h-ピラジノ[1’,2’:4,5]ピラジノ[2,3-c]ピリダジン誘導体
EP4587127A1 (en) * 2022-09-15 2025-07-23 Prelude Therapeutics Incorporated Brm targeting compounds and associated methods of use
US20240190886A1 (en) * 2022-11-15 2024-06-13 Prelude Therapeutics Incorporated BRM Targeting Compounds and Associated Methods of Use
WO2024192064A1 (en) * 2023-03-14 2024-09-19 Oncopia Therapeutics, Inc. D/B/A/ Proteovant Therapeutics, Inc. Compounds and compositions as smarca2/4 degraders and uses thereof
CN120957992A (zh) * 2023-04-07 2025-11-14 南京再明医药有限公司 Brm选择性降解剂化合物
EP4695250A1 (en) 2023-04-12 2026-02-18 Aurigene Oncology Limited Tetracyclic compounds as smarca2 and/or smarca4 degraders
AU2024304006A1 (en) * 2023-06-16 2026-01-08 Plexium, Inc. Compounds and pharmaceutical compositions that degrade swi/snf-related matrix-associated actin-dependent regulator of chromatin subfamily a
AU2024352092A1 (en) 2023-09-28 2026-04-09 Arvinas Operations, Inc. Benzimidazole and benzimidazolone based protac compounds for the targeted degradation of leucine rich repeat kinase 2 (lrrk2)
WO2025101738A1 (en) * 2023-11-07 2025-05-15 Prelude Therapeutics Incorporated Brm targeting compounds and associated methods of use
WO2025106482A1 (en) * 2023-11-13 2025-05-22 Oncopia Therapeutics, Inc. D/B/A Sk Life Science Labs Compounds and compositions as smarca2/4 degraders and uses thereof
WO2025106472A1 (en) * 2023-11-13 2025-05-22 Regents Of The University Of Michigan Compounds and compositions as smarca2/4 degraders and uses thereof
WO2025113460A1 (zh) * 2023-11-28 2025-06-05 西藏海思科制药有限公司 一种哒嗪并三环衍生物及其在医药上的应用
AU2024411627A1 (en) * 2023-12-26 2026-07-16 Gluetacs Therapeutics (Shanghai) Co., Ltd. Compounds with two azaheterocycles substituted isoindolinone skeleton and uses thereof
WO2025184459A1 (en) * 2024-03-01 2025-09-04 Prelude Therapeutics Incorporated Brm and brg1 targeting compounds and associated methods of use
WO2025193454A1 (en) 2024-03-01 2025-09-18 Prelude Therapeutics Incorporated Brm and brg1 targeting antibody-drug conjugates and methods of use thereof
WO2025194405A1 (en) * 2024-03-21 2025-09-25 Prelude Therapeutics Incorporated Polymorphic smarca inhibitors and uses thereof
WO2026136866A1 (en) 2024-12-20 2026-06-25 Prelude Therapeutics Incorporated Kat6 targeting compounds
WO2026151924A1 (en) * 2025-01-09 2026-07-16 Triana Biomedicines, Inc. 2-(2, 6-dioxopiperidine-3-yl)-1, 3-dioxoisoindoline derivatives bearing an heteroaryl group as anaplastic lymphoma kinase (alk) degraders and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107257800A (zh) * 2014-12-23 2017-10-17 达纳-法伯癌症研究所股份有限公司 通过双功能分子诱导靶蛋白降解的方法
WO2019195201A1 (en) * 2018-04-01 2019-10-10 Arvinas Operations, Inc. Brm targeting compounds and associated methods of use

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657744A (en) 1970-05-08 1972-04-25 Univ Minnesota Method for fixing prosthetic implants in a living body
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5040548A (en) 1989-06-01 1991-08-20 Yock Paul G Angioplasty mehtod
US5350395A (en) 1986-04-15 1994-09-27 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US5061273A (en) 1989-06-01 1991-10-29 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US4748982A (en) 1987-01-06 1988-06-07 Advanced Cardiovascular Systems, Inc. Reinforced balloon dilatation catheter with slitted exchange sleeve and method
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
CA1322628C (en) 1988-10-04 1993-10-05 Richard A. Schatz Expandable intraluminal graft
US6344053B1 (en) 1993-12-22 2002-02-05 Medtronic Ave, Inc. Endovascular support device and method
US5674278A (en) 1989-08-24 1997-10-07 Arterial Vascular Engineering, Inc. Endovascular support device
US5292331A (en) 1989-08-24 1994-03-08 Applied Vascular Engineering, Inc. Endovascular support device
GB2554071A (en) 2016-09-14 2018-03-28 Univ Dundee Small molecules
SI3526202T1 (sl) 2016-10-11 2025-04-30 Arvinas Operations, Inc. Spojine in postopki za ciljno razgradnjo androgenskih receptorjev
IL266842B (en) 2016-12-01 2022-09-01 Arvinas Operations Inc History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists
WO2019084026A1 (en) 2017-10-24 2019-05-02 Genentech, Inc. (4-HYDROXYPYRROLIDIN-2-YL) -HETEROCYCLIC COMPOUNDS AND METHODS OF USE
WO2019084030A1 (en) 2017-10-24 2019-05-02 Genentech, Inc. (4-HYDROXYPYRROLIDIN-2-YL) -HYDROXAMATE COMPOUNDS AND METHODS OF USE
SG11202104495YA (en) * 2018-04-26 2021-05-28 Aurigene Discovery Tech Ltd Pyridazine derivatives as smarca2/4 degraders
WO2019213005A1 (en) * 2018-04-30 2019-11-07 Dana-Farber Cancer Institute, Inc. Small molecule degraders of polybromo-1 (pbrm1)
US12454520B2 (en) * 2018-07-06 2025-10-28 Kymera Therapeutics, Inc. Protein degraders and uses thereof
EP3867242A1 (en) 2018-10-15 2021-08-25 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
WO2021133917A1 (en) * 2019-12-23 2021-07-01 Kymera Therapeutics, Inc. Smarca inhibitors and uses thereof
PT4161935T (pt) * 2020-06-09 2025-08-14 Prelude Therapeutics Inc Compostos direcionados a brm e métodos de utilização associados
JP2025521091A (ja) * 2022-05-10 2025-07-08 プレリュード・セラピューティクス・インコーポレイテッド がんの治療のためのsmarca4タンパク質分解因子としての6,6a,7,8,9,10-ヘキサヒドロ-5h-ピラジノ[1’,2’:4,5]ピラジノ[2,3-c]ピリダジン誘導体

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107257800A (zh) * 2014-12-23 2017-10-17 达纳-法伯癌症研究所股份有限公司 通过双功能分子诱导靶蛋白降解的方法
WO2019195201A1 (en) * 2018-04-01 2019-10-10 Arvinas Operations, Inc. Brm targeting compounds and associated methods of use

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116744929A (zh) * 2020-11-20 2023-09-12 福霍恩治疗公司 化合物及其用途
WO2026098598A1 (zh) * 2024-11-08 2026-05-15 正大天晴药业集团股份有限公司 含有三并杂环的化合物

Also Published As

Publication number Publication date
WO2022099117A1 (en) 2022-05-12
AU2021376415A9 (en) 2025-01-09
EP4240743A1 (en) 2023-09-13
CA3200685A1 (en) 2022-05-12
KR20230117577A (ko) 2023-08-08
IL302669A (en) 2023-07-01
AU2021376415A1 (en) 2023-06-22
MX2023005301A (es) 2023-07-18
JP2023549341A (ja) 2023-11-24
US12448389B2 (en) 2025-10-21
US20230083376A1 (en) 2023-03-16

Similar Documents

Publication Publication Date Title
US12448389B2 (en) BRM targeting compounds and associated methods of use
AU2021411587B2 (en) Indazole compounds as kinase inhibitors
CN112166110B (zh) Shp2磷酸酶抑制剂及其使用方法
EP4010335A1 (en) Shp2 inhibitors
IL298933A (en) BRM-targeted compounds and related methods of use
KR20150059647A (ko) 키나제 억제제로서 유용한 이미다조트리아진카르보니트릴
CN119487036A (zh) 作为smarca4蛋白降解剂用于治疗癌症的6,6a,7,8,9,10-六氢-5h-吡嗪并[1',2':4,5]吡嗪并[2,3-c]哒嗪衍生物
KR20250110370A (ko) 암 치료 방법
ES3060156T3 (en) (s)-1-(5-((pyridin-3-yl)thio)pyrazin-2-yl)-4'h,6'h-spiro[piperidine-4,5'-pyrrolo[1,2-b]pyrazol]-4'-amine derivatives and similar compounds as shp2 inhibitors for the treatment of e.g. cancer
CA3225045A1 (en) Her2 mutation inhibitors
WO2022133215A1 (en) Cdk inhibitors and their use as pharmaceuticals
WO2023245150A9 (en) Kat6 targeting compounds with ubiquitin ligase binding moiety
CN120418251A (zh) Brm靶向化合物和相关使用方法
CN119053600A (zh) 用于治疗癌症的杂环化合物
EA052189B1 (ru) Соединения, нацеленные на brm, и связанные с ними способы использования
WO2025101738A1 (en) Brm targeting compounds and associated methods of use
EA050130B1 (ru) Ингибиторы cdk и их применение в качестве лекарственных препаратов

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination